SCHEMBL5449783

SCHEMBL5449783

O=C(O)c1cc(CSc2ccc(F)cc2)on1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.48
L3MBTL1 Q9Y468 4/20 0.46
HPGD P15428 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 2/20 0.42
RECQL P46063 1/20 0.42
THRB P10828 1/20 0.42
CXCR2 P25025 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461144 0.85 MEN1 (0.54) L3MBTL1ALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL5458534 0.85 MEN1 (0.60) DAOL3MBTL1HPGDALDH1A1LMNA
SCHEMBL5448449 0.85 THRB (0.48) DAOL3MBTL1HPGDALDH1A1LMNA
SCHEMBL5445311 0.85 PPARD (0.53) LMNASMN1; SMN2NPC1RAB9ACYP2C9
SCHEMBL5445324 0.82 ALDH1A1 (0.55) DAOHPGDALDH1A1LMNASMN1; SMN2
SCHEMBL15931904 0.77 THRB (0.51) L3MBTL1ALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL5460248 0.76 L3MBTL1 (0.61) L3MBTL1ALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL18010609 0.76 THRB (0.50) L3MBTL1SMN1; SMN2NPC1RAB9ATHRB
SCHEMBL15931975 0.73 NPC1 (0.60) DAOL3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL5451857 0.73 ALDH1A1 (0.55) HPGDALDH1A1LMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US claimed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP claimed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO claimed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP disclosed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors PDF, MRPL21, PEPD DAO 476/4885L3MBTL1 4489/4885HPGD 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.